Presentation Abstract

Session: Advances in PET Amyloid Imaging
Sunday, Jul 11, 2010, 1:00 PM - 3:00 PM
Presentation: O1-02-02 - 18F-Florbetaben-PET imaging in the differential diagnosis of dementia
Pres. Time: Sunday, Jul 11, 2010, 1:15 PM - 1:30 PM
Location: Hall 1
Category: +Differential diagnosis
Author(s): Victor L. Villemagne, MD1,2, Kevin Ong, MD1, Narelle Langdon, RN1, Gerhard Holl, MD3, Cornelia Reininger, MD3, Barbara Putz, PhD3, Gareth Jones1, Thomas Dyrks, PhD3, Ludger Dinkelborg, PhD3, Uwe Ackermann, PhD1, Rachel Mulligan, PhD1, Graeme O'Keefe, PhD1, Beate Rohde, PhD3, Colin L. Masters, MD2, Christopher Rowe, MD1.
1Austin Hospital, Melbourne, VIC, Australia, 2The Mental Health Research Institute, Melbourne, VIC, Australia, 3Bayer Schering Pharma, Berlin, Germany.
Abstract: Background:
Amyloid imaging with F18 radiotracers will allow widespread use of the technique, facilitating research into the causes, diagnosis, and treatment monitoring of dementias, where Aβ may play a role. The purpose of the study was to compare cortical amyloid deposition in healthy control subjects (HC), dementia with Lewy Body (DLB), frontotemporal lobar degeneration (FTLD), and Alzheimer’s disease (AD) patients in-vivo using 18F-Florbetaben and PET.
AD (n=26), FTLD (n=11) and DLB (n=6) patients as well as HC (n=26) underwent PET imaging after iv injection of 300 MBq 18F-Florbetaben. Standard uptake value ratios (SUVR) using the cerebellar cortex as reference region were calculated between 90-120 min post injection.
Significantly higher SUVR in neocortical areas were observed in AD patients when compared with the other groups. Most AD patients (96%) showed diffuse cortical 18F-Florbetaben retention while 85% of HC, 91% of FTLD, and 67% of DLB subjects showed only white-matter binding.
Cortical Aβ is present in most AD subjects with progressive dementia, while FTLD subjects show no cortical 18F-Florbetaben retention. 18F-Florbetaben clearly dstinguished subjects with high Aβ burden from those with low Aβ burden. Longitudinal studies will establish the value of 18F-Florbetaben in predicting development of dementia.
Disclosures:   V.L. Villemagne, NHMRC Grant 509166, Grants/Research Support; Bayer Schering Pharma, Consultant; K. Ong, None; N. Langdon, None; G. Holl, Bayer Schering Pharma, Employee; C. Reininger, Bayer Schering Pharma, Employee; B. Putz, Bayer Schering Pharma, Employee; G. Jones, None; T. Dyrks, Bayer Schering Pharma, Employee; L. Dinkelborg, Bayer Schering Pharma, Employee; U. Ackermann, None; R. Mulligan, NHMRC Grant 509166, Grants/Research Support; NHMRC Grant 509166, Other financial or material support; G. O'Keefe, None; B. Rohde, Bayer Schering Pharma, Employee; C.L. Masters, None; C. Rowe, Bayer Schering Pharma, Consultant.
EMBARGO: As a reminder: All abstracts accepted for presentation at ICAD are embargoed until the date and time of presentation at the conference, unless the Alzheimer's Association provides written notice of change of date and/or time in advance. Embargo is the prohibition for copyright reasons from releasing any content from a submitted or accepted abstract to the public until after it has been presented at ICAD. Prior to presentation at ICAD, authors may not release information to the news media or the public, nor publish the results in any manner, and must ensure that colleagues and other organizations or institutions are aware of this policy. Violation of the embargo may include retraction of the accepted abstract and/or loss of privileges of presenting research at ICAD in the future.

Technical Support
Phone: 217-398-1792